FDA Relocates To Lake Wobegon? Most Applications Deemed Above Average, Researchers Find
Executive Summary
Studies cite routine use of special review programs for drugs that are not first in class and less rigorous requirements for approval of supplemental applications.
You may also be interested in...
FDA Science Board's Report: Legislative Negotiating Tactic, Or Just Whining For Money?
21st Century Cures criticized by FDA advisors for unfunded mandates, but legislation also represents best near-term prospect for reforms of the kind the report envisions.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.